| Abstract [eng] |
Cervical cancer is the second oncological disease in women in the world, and the fourth one in Lithuania. The main cause of the cervical cancer is Human papillomavirus (HPV) infection in the cervix uteri. In order to detect precancerous changes or cancer cells, a Papanicolaou (Pap) test based on cytology and HPV DNA test are used in the Western world. Currently used HPV diagnostic tests are based on molecular biology testing methods. The polymerase chain reaction (PCR) method, not the extensively used Hybrid Capture 2 (HC2) method awarded the certificate of quality by both the USA and Europe, was chosen. PCR is a particularly sensitive, fast, and commercially available method that needs a small quantity of research material and can identify the types of HPV. HC2 method does not detect HPV genotypes, false-negative results are possible because there is no internal control, and due to cross reactions, false-positive results are possible. The newest written sources state that PCR will have much potential in the future and it is thought that HPV detection standard will become 14 HR-HPV test combined with the detection of the types of HPV-16 and HPV-18. Therefore, in order to chose the optimum one for HPV tests from the commercial kits offered in Lithuania, this investigation was carried out in the National Centre of Pathology. Four different HPV diagnostic kits were used for the research. Having evaluated the research results, „Seeplex® HPV4A ACE Screening“ HPV diagnostic kit was chosen for further investigation. |
